scholarly journals One-Year Outcomes Comparing Anti-VEGF Monotherapy and Combined Anti-VEGF+Photodynamic Therapy for Retinal Angiomatous Proliferation

2017 ◽  
Author(s):  
Cem Kesim
Keyword(s):  
Photodynamic Therapy ◽  
Retinal Angiomatous Proliferation ◽  
Anti Vegf ◽  
One Year

scholarly journals Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy

2021 ◽  
Vol 10 (10) ◽  
pp. 2168
Author(s):  
Koji Tanaka ◽  
Ryusaburo Mori ◽  
Yu Wakatsuki ◽  
Hajime Onoe ◽  
Akiyuki Kawamura ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Photodynamic Therapy ◽  
Choroidal Thickness ◽  
Retinal Thickness ◽  
Serous Retinal Detachment ◽  
Additional Treatment ◽  
Conventional Dose ◽  
Anti Vegf ◽  
Pachychoroid Neovasculopathy ◽  
One Year

Pachychoroid neovasculopathy (PNV) is treated with antivascular endothelial growth factor (VEGF) injection and photodynamic therapy (PDT), but no curative treatment has yet been established. We aimed to clarify the treatment results of a reduced dose of PDT for PNV. The subjects were 27 eyes of 27 patients (male:female = 20:7, mean age 58.9 years). PDT, at 2/3 of the conventional dose (2/3PDT), was administered once. The patients were then observed for one year. Eyes with polypoidal choroidal vasculopathy (PCV) were excluded. We investigated the associations among the central retinal thickness, choroidal thickness, and visual acuity changes before treatment and one, three, six and 12 months after PDT. When serous retinal detachment was increased or unchanged or new hemorrhages were observed, as compared with pretreatment findings, intravitreal injection of an anti-VEGF agent was performed. Visual acuity was significantly improved, as compared to before treatment, at three, six, and 12 months after 2/3PDT. Foveal retinal thickness was significantly decreased after versus before treatment in the 2/3PDT group (p < 0.001). Foveal choroidal thickness was also significantly reduced in the 2/3PDT group (p = 0.001). Additional intravitreal anti-VEGF agent injections were administered to three patients (11%), while 24 (89%) required no additional treatment during the one-year follow-up period. For PNV without polyps, 2/3PDT appears to be effective.

scholarly journals One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jirarattanasopa Pichai ◽  
Banchasakjaroen Vanchalerm ◽  
Ratanasukon Mansing
Keyword(s):  
Photodynamic Therapy ◽  
Recurrence Rate ◽  
Central Serous Chorioretinopathy ◽  
Subretinal Fluid ◽  
Corrected Visual Acuity ◽  
Half Dose ◽  
One Year ◽  
The One ◽  
Different Doses

Abstract Background Central serous chorioretinopathy (CSC) is characterized by an accumulation of subretinal fluid (SRF) in the macula. It is usually treated by laser photocoagulation or photodynamic therapy (PDT) with consisting of different doses and power. This study aimed to compare the efficacy of half-dose PDT and one-third-dose PDT in chronic or recurrent CSC. Methods A retrospective review of patients with chronic or recurrent CSC who were treated with either a half-dose or one-third-dose PDT, and had follow up 12 months afterwards. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and resolution of subretinal fluid (SRF) at baseline as well as 1, 3, 6 and 12 months post-PDT were assessed. Results Forty-six eyes and 20 eyes received half-dose and one-third-dose PDT, respectively. The study showed efficacy of the one-third-dose PDT compared with half-dose PDT in BCVA improvement (0.10±0.04 logMAR for one-third-dose versus 0.17±0.04, for half-dose, P=0.148) and CRT improvement (125.6±24.6 μm for one-third-dose versus 139.1±16.54, for half-dose, P=0.933) at 12 months. The SRF recurrence rate was significantly higher in the one-third-dose PDT group compared with the half-dose PDT group (40.0% versus 15.2%, P=0.027) at 12-months. Conclusion At 12 months, the one-third-dose PDT was effective in terms of BCVA and CRT improvement, when compared with half-dose PDT. However, this study showed that one-third-dose PDT had a higher recurrence rate of SRF.

Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation

2008 ◽  
Vol 146 (6) ◽  
pp. 935-941.e1 ◽  
Author(s):  
Masaaki Saito ◽  
Chieko Shiragami ◽  
Fumio Shiraga ◽  
Dai Nagayama ◽  
Tomohiro Iida
Keyword(s):  
Photodynamic Therapy ◽  
Intravitreal Bevacizumab ◽  
Retinal Angiomatous Proliferation

scholarly journals Treatment of head and neck cancer with photodynamic therapy: results after one year

1995 ◽  
Vol 109 (11) ◽  
pp. 1072-1076 ◽  
Author(s):  
M. G. Dtlkes ◽  
M. L. DeJode ◽  
Q. Gardiner ◽  
G. S. Kenyon ◽  
P. McKelvie
Keyword(s):  
Head And Neck Cancer ◽  
Photodynamic Therapy ◽  
Head And Neck ◽  
Neck Cancer ◽  
First Generation ◽  
Sufficient Evidence ◽  
Clinical Responses ◽  
Promising Treatment ◽  
One Year ◽  
Multicentre Prospective Study

AbstractPhotodynamic therapy (PDT) is a new and promising treatment modality for the treatment of malignant disease. This paper reports the preliminary experience of our group in the use of this therapy for the treatment of tumours arising in the head and neck. The majority of treatments in these cases have used a second generation systemic photosensitizer, meta-tetrahydroxyphenylchlorin (m-THPC). Two other cases were treated with either Photofrin 2 (a first generation systemic sensitizer) or with the topical photosensitizer, delta-aminolaevulinic acid (δ-ALA).The initial results have been encouraging with good clinical responses evident in patients presenting with a variety of differing tumour types. We feel there is now sufficient evidence of the efficacy of this treatment to warrant a multicentre prospective study into the treatment of early head and neck cancer with PDT.

Sign in / Sign up

Export Citation Format

Share Document